Plain-English translation of NCT07300683 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called anti-CCR9 CAR T cells for people with T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma that has returned or stopped responding to standard chemotherapy. The medication is made by taking your own immune cells, training them in a laboratory to recognize and fight cancer cells, and then putting them back into your body. Researchers want to see if this treatment is safe and what the best dose should be.
T cell leukemias and lymphomas are aggressive cancers that often come back or stop responding to standard chemotherapy, leaving patients with limited options. This trial exists to explore whether engineered immune cells targeting a specific marker on cancer cells could offer a new, potentially more effective treatment path.
You likely qualify if…
You likely don't qualify if…
You will have blood cells collected and sent to a laboratory where they are engineered to become cancer-fighting cells. About a week before receiving the engineered cells, you will be admitted to the hospital for a short course of preparatory chemotherapy. You will then receive an infusion of your engineered cells through an IV and stay in the hospital for at least 2 weeks for close monitoring. After going home, you will return to the clinic for check-ups (about 12 visits over the first two years), during which you'll have blood tests, physical exams, and possibly scans or bone marrow biopsies depending on your type of cancer.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United Kingdom